Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 31, 2007

View Archived Issues

New therapeutic agents for myeloproliferative disorders described in recent Exelixis patent

Recent patents disclose novel treatment options for cardiovascular disorders

Results of phase III studies of galantamine in Alzheimer's disease reported

PKMzeta activity appears necessary for long-term memory maintenance

Ambrilia reports update on clinical trials of prolonged release octreotide

Novel compounds with chaperone activity may be useful in Gaucher's disease

Second generation HCV protease inhibitors described by Schering-Plough

New Akt inhibitors with antitumor potential described by Pfizer

Patient enrollment begins for phase II study of IMC-A12 in advanced prostate cancer

NDA for Merck & Co.'s lipid-modifier, Cordaptive, accepted for review

Memory Pharmaceuticals begins phase I clinical trial of R-4996/MEM-63908

Orexo's treatment for nocturia/incontinence enters phase I

New six-month dosage for MediGene's Eligard receives pan-European approval

Discovery of xanthine-based DPP-IV inhibitor BI-1356 discussed at ACS meeting

Treanda granted U.S. orphan drug designation for CLL

Aspreva and Roche adjust and expand CellCept agreement

GW completes patient recruitment for pivotal phase III trial of Sativex

Baxter and ADCS group agree to initiate phase III study of Gammagard Liquid

Lorus completes proof of concept trial of GTI-2040 for AML; begins phase II trial

Prolexys begins phase I study of PRLX-93936 for solid tumors

Somatuline Depot approved in U.S. for acromegaly

Positive results from phase III study of Vidaza for MDS

Pharming reports positive interim results from phase III trial of Rhucin for HAE

BioDiem begins four studies of BDM-E at Monash University

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...